Understanding Xolair for Nasal Polyps: What FDA Approval and Science Means

Understanding Xolair for Nasal Polyps: What FDA Approval and Science Means

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4% of adults worldwide, causing nasal congestion, loss of smell and facial pressure. If you've tried nasal corticosteroids or surgery and still have symptoms, Xolair (omalizumab) offers a targeted treatment option. Below is a clear, concise overview of what the FDA approval means, how Xolair works, its dosage, and what science tells us about its benefits and risks.

---

What Are Nasal Polyps?

Nasal polyps are non-cancerous, teardrop-shaped growths that form in the lining of the nose or sinuses. They result from chronic inflammation and can:

• Block nasal passages
• Lead to breathing difficulties
• Reduce or eliminate sense of smell
• Increase risk of sinus infections

Standard treatments include nasal corticosteroids, saline rinses and, in severe cases, endoscopic sinus surgery. Yet, many patients experience recurrent symptoms despite these therapies.

---

What Is Xolair?

Xolair (generic name: omalizumab) is a monoclonal antibody that targets immunoglobulin E (IgE), a key driver of allergic inflammation. Originally approved for allergic asthma in 2003, Xolair received expanded FDA approval in June 2020 for adults (≥18 years) with inadequately controlled nasal polyps despite intranasal steroids.

Key points:

• Targets free IgE in blood → prevents IgE from binding to receptors on inflammatory cells
• Reduces release of histamine, leukotrienes and other inflammatory mediators
• Administered by subcutaneous injection every 2 or 4 weeks

---

FDA Approval for Nasal Polyps

In June 2020, the U.S. Food and Drug Administration (FDA) approved Xolair as an add-on maintenance treatment for adults with CRSwNP who remain symptomatic despite nasal corticosteroids.

Approval was based on two pivotal phase 3 trials (SINUS-24 and SINUS-52):

• Randomized, double-blind, placebo-controlled studies
• Enrolled patients with moderate to severe CRSwNP
• Showed significant reduction in nasal polyp size and symptom scores
• Demonstrated improvement in sense of smell and quality of life
• Maintained benefits through 24 or 52 weeks of treatment

---

Xolair for Nasal Polyps Dosage

Xolair dosing for nasal polyps mirrors its asthma indication, determined by body weight and baseline serum IgE levels:

Body Weight (kg)	Total Serum IgE (IU/mL)	Dose (mg)	Frequency
30 – 90	30 – 700	150	Every 4 weeks
30 – 150	30 – 700	300	Every 4 weeks
30 – 90	30 – 1,500	150	Every 2 weeks
90 – 150	30 – 1,500	300	Every 2 weeks

• Dosing table adapted from the Xolair FDA Prescribing Information (2020).
• Maximum single dose: 300 mg.
• Treatment should be supervised by a healthcare professional experienced in biologic therapies.

---

How Xolair Works (The Science)

1. IgE Binding: Xolair binds to the Cε3 domain of free IgE molecules, preventing them from attaching to high‐affinity IgE receptors (FcεRI) on mast cells and basophils.
2. Receptor Downregulation: Reduced free IgE leads to decreased FcεRI expression on inflammatory cells, further dampening allergic cascades.
3. Decreased Mediator Release: With fewer IgE‐FcεRI interactions, there's less histamine and leukotriene release—key drivers of tissue swelling and polyp formation.
4. Chronic Inflammation Control: Over weeks to months, this mechanism reduces mucosal edema and polyp burden, improving nasal airflow and smell.

---

Efficacy and Safety

Benefits Demonstrated in Clinical Trials

• ≥50% reduction in nasal polyp score vs. placebo
• Improved nasal congestion scores
• Faster and sustained improvement in sense of smell
• Reduced need for systemic corticosteroids and sinus surgery

Common Side Effects

• Injection site reactions (pain, redness, swelling)
• Headache
• Viral upper respiratory tract infections
• Arthralgia (joint pain)
• Rare: anaphylaxis (incidence <0.1%)

Your healthcare provider will monitor for allergic reactions—especially after the first 3 injections when risk is highest.

---

Who May Benefit from Xolair?

Consider discussing Xolair with your doctor if you:

• Are an adult (≥18 years) with CRSwNP
• Have persistent nasal congestion or loss of smell despite intranasal steroids
• Have undergone sinus surgery with recurrent polyps
• Have elevated serum IgE within the dosing range (30–1,500 IU/mL)
• Are seeking to reduce systemic corticosteroid use

---

Next Steps and Practical Tips

1. Evaluation: A thorough ENT (ear, nose, throat) assessment and blood test for total IgE.
2. Insurance and Cost: Xolair may require prior authorization; copay assistance programs are often available.
3. Administration: Given by trained staff in a clinic or self-administered after proper instruction.
4. Monitoring: Regular follow-up every 2–4 weeks to assess symptom improvement and side effects.

If you're struggling with ongoing nasal congestion, facial pressure, or loss of smell and want to understand your symptoms better, use Ubie's free AI symptom checker to help identify potential causes and prepare meaningful questions for your ENT appointment.

---

Important Reminder

This information is for educational purposes and does not replace medical advice. If you experience severe shortness of breath, facial swelling, hives, chest tightness or any symptom that feels life threatening, seek emergency care immediately. Always speak to your doctor before starting or changing treatments for nasal polyps.

Talk with your healthcare provider to determine if Xolair is appropriate for your condition and to develop a comprehensive treatment plan tailored to your needs.